Covid-Shield PI ™ Currently in human clinical trials*





Multi-Drug Combination, Passive Immunization Treatment all active ingredients are FDA approved for their normal Label Use – This treatment is Off Label Use and has not yet been Approved by the FDA for use in Passive Immunization via receptor blocking agonist strategy

A Patent Pend and Trade Mark Approved Product of ENKS New Technology Holdings

Technical discussion on Covid-Shield PI (Passive Immunity) Multi drug combination, prophylactic therapy

The unique combination drug therapy which is comprised of multiple FDA approved on-label Drugs currently in circulation around the world for decades, with a long histories of efficacy and safety, do in fact produce a synergistic effect, (when combined together in the presence of additional ingredients which are equally safe and effective according to long historical analysis), produce a form of **"passive immunity"** for the person consuming a medium or long term dose regime (4-8 months during flu or pandemic wave season) of Covid-Shield PI, Combination Prophylactic Drug Therapy, (creating a Passive Immunity to Novel Coronavirus Covid19).

The unique combination drug therapy has been designed based on scientific evidence which has revealed the methodology by which the novel SARS coronavirus (COVID-19) infects human cells, the primary pathway utilized by this novel coronavirus pandemic pathogen is through a ACE - 2 receptor binding pathway, as well as other mediators, and once infecting human cells, the pathogen replicate and proliferates to the point of triggering a significant immune reaction in the infected host/person.

The problem with this novel SARS coronavirus (COVID-19), is that it does not behave in all respects as a common virus or, a known pathogen, due to the fact that it utilizes a unique pathway for infection, while creating potential fatal consequences and multiple negative pathologies, by virtue of the significant provocation of the human Immune system complex, to such a degree, that it has manifested in many different forms across many different demographic categories (elderly, youth, children, and others, of all ethnicities), these potentially fatal side effects of COVID-19 infection include, but are not limited to, the fatal effects of "cytokine storm", which once triggered can quickly cause death in an infected person, due to the violent inflammatory reaction associated with "cytokine storm".

The unfortunate consequences of the above side effects, related to significant provocation of the immune system response are problematic, due to the fact that they present themselves in multiple ways, confusing common clinical diagnoses and determinations, confusing the best treatment options needed for deployment, in order to save infected patients.

An example of this, may be that in many cases of intubation and ventilation, patients on ventilators have proven have a marked increase of morbidity (death), due to the fact that the oxygen perfusion, the transfer of oxygen between the lung tissue and the bloodstream, is not being prevented due to a mechanical defect, or only a mucosal obstruction, but primarily due to a mass inflammatory response, within the minute structures of the lung tissue itself and in many cases if not all, there is at least some thrombosis present in capillary systems, and other thrombotic related events, diffuse across the body, affecting not only the lungs, but in many cases, the heart, brain, kidneys, and other organs as well.

This has become a common symbolic pathology, of this novel coronavirus infection, and therefore the need for prevention has increased greatly, due to the fact that it is a very dangerous pathogen, and once a person has been infected, is very challenging to eradicate, control, and prevent the death of the infected patients, due to the diverse damage inflicted by this pathogen on some, or most, of the vulnerable demographic populations.

The treatment in an ICU setting for COVID-19 patients have evolved considerably, due to the real time emergence of new information and studies yielding more clarity towards the actual function and proliferation of COVID-19 we find another example, of which is that only several known drugs, such as Actemra, or interferon alpha-2b, (one being an inflammation mediator, and the other being more specific for interleukin 6 receptor site binding), both contributing to the arrest and/or reversal, or at least, minimization of cytokine storm damage when administered early and under controlled monitoring.

This has been a very positive development as all of the Covid shield PI components, (active ingredients) have also shown significant promise, in suppressing the severity of moderately ill patients, without the use of Actemra or interferon alpha-2b in clinical a setting when administered after infection and more importantly, it has s clear Passive Immunity against the Covid 19 Pathogen in Patients who have not yet been exposed or infected.

Covid-Shield PI, can also be used combination with Actemra or interferon alpha-2b treatment protocol, to reduce the severe infections and inflammation response and potential morbidity, as well as being used as a prophylactic, preventing the infection in the first place, through the presentation of passive immunity, produced by the effects of Covid shield PI, receptor blocking properties, and other inflammation mediators, immune system stabilizers, and metabolic support components, all being a part of the full spectrum approach, of the combined drug therapy treatment, which is Covid-Shield PI (Passive Immunity).

The company hopes that Covid shield PI, will become a benchmark prophylactic treatment for all vulnerable demographics and “essential worker” categories, as well as others, with may wish to participate in a safe and effective drug regime, producing a prophylactic passive immunity and while not being a vaccine, it may be the next best thing, producing a protective barrier between the individual and the viral pathogen COVID-19 using a new methodology – acting in a very similar role of a classic Vaccine.

The efficacy in-vitro and in-vivo study, show reproducible results of 85% to 90+% efficiency in the complete blocking and/or suppression of infection by COVID-19 in susceptible populations, and this percentage is acceptable, due to the fact that it actually exceeds the percentile ratio, and effectiveness as claimed by seasonal flu vaccine and other related vaccines, used over the previous decade, by considerable degree.

As an example, the flu vaccine/flu shot, has an effectiveness of not more than 65% best and 40% at worst based on Decades of statistical Data.

Therefore, Covid shield PI, has shown so far to be a greatly more effective in preventing infection or mediating it severity, than vaccine therapy itself per se, using what may even be a safer pathway, blocking the ability of COVID-19 to infect humans cells, as well as mediating and limiting the effects of such infections, if it should occur, thereby protecting the patient or person from a potentially morbid effects and even death associated with this virulent strain of this novel SARS coronavirus (COVID-19).

Potential Risk Factors Examined:

The only scientific argument for concern, has been the concept of “potential interaction” (negative side effects), between the active ingredients of Covid - Shield PI, which is a combination drug therapy, prophylactic passive immunity regime.

The results of this review has proven that the active components of Covid-Shield PI, have little or no interactivity, or contraindications, between the respective combined active ingredients, (all of which are FDA approved for their own label use, the approved for off label use in combined drug therapy presentations such as Covid shield PI has not yet been FDA approved while we are confident it will be in the very near future due to the face that the Multi Drug Combination has decades of historical statistics on safety and interactions as well as contraindications and / or side effects- due to the face that all of the active ingredients of Covid- Shield PI have long been approved by the FDA for On-label use).

The effectiveness is clear as is the the lack of significant contraindications or side effects or interactions between any of the combined components, this being a very positive outcome as to safety and effectiveness and gives the company a hopeful and positive view, as to regulatory approval and/or exemptions from regulatory approval, for off label use, or other exemptions, this as well as the urgent regulatory review atmosphere, created by the violent nature of the current global pandemic, the COVID-19 plague which has presented the global health community and the global population with a stark choice to balance, administrative and long term trials and studies, between a balanced short-term, scientific review, filtering out any dangerous therapy candidate, for the protection of the population, this balance must be stuck in a pragmatic manner, using only scientific data and comparative analysis, as the tools to decide whether an alternate methodology, or another treatment regime, is in fact safe enough to release for mass consumption, across the most vulnerable demographic categories.

We believe that Covid shield PI, is one of those drugs and one of those treatment regimens which fall under the category of having a permissible level of safety and efficacy, which the global population deserves to have available, to protect them and their families from potential infection by this virulent strain of novel coronavirus COVID-19 pathogen.

In the coming weeks, the company intends to aggressively pursue, together with our scientific and medical expert partners and associates, regulatory and administrative authorities in various countries around the world, in an effort to increase and enhance human trial participation using Covid shield PI, with the goal being to provide this treatment option to the broadest demographic populations who need it the most as soon as possible with the least regulatory/administrative delays, while in keeping with the highest level of safety and efficacy standards, utilizing scientific data and actual results as a guide, in addition to historical comparable data, which significantly support our projected opinion, that Covid shield PI is in fact a new and potentially revolutionary treatment to protect against the infection by COVID-19 as well a legitimate and effective treatment to mediate and suppress the potential deadly effects of the pathogen in the case of a person who has already been infected and therefore, we feel that we are obligated to do our best, in bringing forward in a safe and effective legal and balanced manner, the Covid -Shield PI combination drug therapy as a prophylactic passive immunity drug regime product, and in addition we will be adding other support products, to the company's sectors targets which would entail other types of mediating products, such as specialized saline nasal spray, currently approved by the FDA for over the counter use, as well as specially prepared mouthwash and gargle preparations, also currently approved for over the counter use, all these to be used in combination with the Covid shield PI combination drug therapy, over periods of high risk of infections throughout the year (between 4 to 8 months depending on seasonal cycles for coronavirus infections, including this particular SARS novel coronavirus COVID-19 pathogen).

In conclusion, we should publicize an expanded white paper and technical review for public discussion and peer review, during the coming weeks, while enhancing our drive towards market access, to the prescribing medical community and consumers who need to be protected from the SARS novel coronavirus known as "COVID-19".

THANK YOU